These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 36243868)

  • 1. COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection.
    Chi WY; Li YD; Huang HC; Chan TEH; Chow SY; Su JH; Ferrall L; Hung CF; Wu TC
    J Biomed Sci; 2022 Oct; 29(1):82. PubMed ID: 36243868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
    Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
    Gong W; Parkkila S; Wu X; Aspatwar A
    Int Rev Immunol; 2023; 42(6):393-414. PubMed ID: 35635216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
    Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA
    Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccines against SARS-CoV-2 variants and future pandemics.
    Park T; Hwang H; Moon S; Kang SG; Song S; Kim YH; Kim H; Ko EJ; Yoon SD; Kang SM; Hwang HS
    Expert Rev Vaccines; 2022 Oct; 21(10):1363-1376. PubMed ID: 35924678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Need of booster vaccine doses to counteract the emergence of SARS-CoV-2 variants in the context of the Omicron variant and increasing COVID-19 cases: An update.
    Mohapatra RK; El-Shall NA; Tiwari R; Nainu F; Kandi V; Sarangi AK; Mohammed TA; Desingu PA; Chakraborty C; Dhama K
    Hum Vaccin Immunother; 2022 Nov; 18(5):2065824. PubMed ID: 35594528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
    Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
    Elife; 2021 Oct; 10():. PubMed ID: 34636722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis.
    Liu Q; Qin C; Liu M; Liu J
    Infect Dis Poverty; 2021 Nov; 10(1):132. PubMed ID: 34776011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death.
    Huang Z; Xu S; Liu J; Wu L; Qiu J; Wang N; Ren J; Li Z; Guo X; Tao F; Chen J; Lu D; Sun X; Wang W
    BMC Med; 2022 Oct; 20(1):400. PubMed ID: 36266697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
    Abu-Raddad LJ; Chemaitelly H; Ayoub HH; AlMukdad S; Yassine HM; Al-Khatib HA; Smatti MK; Tang P; Hasan MR; Coyle P; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R
    N Engl J Med; 2022 May; 386(19):1804-1816. PubMed ID: 35263534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants.
    Noor R
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36423150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review.
    Chen Z; Zhang Y; Wang M; Islam MS; Liao P; Hu Y; Chen X
    Int J Biol Sci; 2022; 18(12):4629-4641. PubMed ID: 35874952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleocapsid as a next-generation COVID-19 vaccine candidate.
    Oronsky B; Larson C; Caroen S; Hedjran F; Sanchez A; Prokopenko E; Reid T
    Int J Infect Dis; 2022 Sep; 122():529-530. PubMed ID: 35788417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants.
    Li T; Luo KQ
    Int J Biol Sci; 2022; 18(12):4642-4647. PubMed ID: 35874950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines.
    McLean G; Kamil J; Lee B; Moore P; Schulz TF; Muik A; Sahin U; Türeci Ö; Pather S
    mBio; 2022 Apr; 13(2):e0297921. PubMed ID: 35352979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis.
    Zou Y; Huang D; Jiang Q; Guo Y; Chen C
    Front Public Health; 2022; 10():940956. PubMed ID: 35910897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.